Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Central Drug Regulator...

    Central Drug Regulator directs states, UTs to ban sale, manufacture, ad of e cigarettes

    Meghna A SinghaniaWritten by Meghna A Singhania Published On 2019-03-13T09:30:18+05:30  |  Updated On 16 Aug 2021 2:05 PM IST

    In August last year, the Health Ministry issued an advisory to all states and UTs to stop the manufacture, sale and import of ENDS after the Delhi HC took a strong exception to the Centre for the delay in coming up with appropriate measures to tackle the "new emerging threat" of e cigarettes in the country.


    New Delhi: The Central Drug Regulator has directed all drug controllers in states and Union territories to not allow the manufacture, sale, import and advertisement of Electronic Nicotine Delivery Systems, including e-cigarettes and flavoured hookah, in their jurisdictions.


    "Since no Electronic Nicotine Delivery Systems (ENDS), including e-cigarettes, heat-not-burn devices, vape, e-sheesha, e-nicotine flavoured hookah, and the like products have not yet been approved under the Drugs and Cosmetics Act 1940 and rules made thereunder, you are requested to ensure devices that enable nicotine delivery are not sold (including online sale), manufactured, distributed, traded, imported and advertised in your jurisdictions," the regulator's order stated.


    Read Also: US FDA to strictly monitor sale of flavoured e-cigarettes


    In August last year, the Health Ministry issued an advisory to all states and UTs to stop the manufacture, sale and import of ENDS after the Delhi HC took a strong exception to the Centre for the delay in coming up with appropriate measures to tackle the "new emerging threat" of e-cigarettes in the country.


    ENDS are devices that heat a solution to create an aerosol, which also frequently contains flavours, usually dissolved into propylene glycol and glycerin.


    Electronic cigarettes or e-cigarettes, the most common prototype, are devices that do not burn or use tobacco leaves but instead vaporise a solution, which a user then inhales.


    The main constituents of the solution, in addition to nicotine, are propylene glycol (with or without glycerol and flavouring agents).


    After the MoHFW advisory, the Ministry of Electronics and Information Technology, too, proposed an amendment to the Information Technology (Intermediary Guidelines) Rules 2018 to ban the advertisement of e-cigarettes.


    Read Also: Health ministry calls for halting sales of e-cigarettes, smoking devices


    Even the Central Board of Indirect Taxes and Customs issued a circular recently, saying that all import consignments of e-cigarettes must be cleared by the drug controller first.


    Steadfast in its commitment to protect the health of children, adolescents and women of reproductive age, 36 countries around the world and 12 states in India have banned the sale of e-cigarettes due to its health harms.


    In India, Punjab, Maharashtra, Karnataka, Kerala, Bihar, Uttar Pradesh, Jammu & Kashmir, Himachal Pradesh, Tamil Nadu, Puducherry and Jharkhand have taken steps to ban the use of ENDS.


    "Nicotine is highly toxic chemical and potentially carcinogenic. In fact, it will not be an exaggeration if it is considered as a poison. Therefore, any nicotine product should be taken under strict medical supervision for controlling withdrawal symptoms during cessation therapy. I laud government of India for taking us a tough stand against these newer nicotine delivery devices," Pankaj Chaturvedi, oncologist, Tata Memorial Hospital, said.


    The increasing popularity of Electronic Nicotine Delivery Systems (ENDS), more commonly known as e-cigarettes or "vapes", threatens to undermine recent progress on tobacco control in India.


    E-cigarettes do not fall within the scope of existing national legislation on tobacco production, distribution, and use, yet pose significant health risks to users that are frighteningly similar to those of conventional cigarettes.


    As per a report prepared by the World Health Organisation, ENDS emits nicotine, the addictive component of tobacco products. In addition to dependence, nicotine can have adverse effects on the development of the foetus during pregnancy and may contribute to cardiovascular disease.


    There is no substantial evidence to prove that ENDS work for cessation and are less harmful than the tobacco products, Prakash C Gupta, director of Healis Sekhsaria Institute of Public Health, said.


    "Naming 'e-cigarette' is a tactic used by the industry to fool media and public by giving it a tubular shape and putting a red LED at the tip which lights up when the tube is sucked to mimic cigarette smoking.


    "It is as incorrect to call it a tobacco product as calling penicillin, a fungal product. It is a nicotine delivery device and ought to be regulated as such," Gupta said.

    Central Drug RegulatorDrug controllersDrugs and Cosmetics Act 1940e cigarettes bane nicotine flavoured hookahe sheeshae-cigaretteselectronic cigaretteselectronic nicotine delivery systemsendsglycerinheat not burn devicesMinistry of Electronics and Information TechnologynicotinePankaj Chaturvedi oncologistpenicillinpropylene glycolTata Memorial HospitalUTvapeWHOWorld Health Organisation
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Meghna A Singhania
    Meghna A Singhania

      Meghna A Singhania is the founder and Editor-in-Chief at Medical Dialogues. An Economics graduate from Delhi University and a post graduate from London School of Economics and Political Science, her key research interest lies in health economics, and policy making in health and medical sector in the country. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok